Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy

M. R. Laftavi, S. Patel, M. R. Soliman, Muna A Alnimri, R. Kohli, M. Said, O. Pankewycz

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Current immunosuppressive therapies and protocols have led to significant improvements in early patient and graft survival rates following kidney transplantation. Whether induction therapies such as rabbit anti-thymocyte globulin (rATG) contribute to these improved results remains controversial. Full-dose rATG induction therapy (710 mg/kg) has been associated with increased morbidity, which may be especially true in a high-risk population such as the elderly. Therefore, we studied the efficacy and tolerability of a low-dose rATG induction strategy in 45 older recipients (>65 years) compared to 45 concurrently transplanted younger patients (<65 years). Both groups received a similar low-dose of rATG induction therapy (older: 2.96 ± 1.29 vs younger: 3.2 ± 2.11 mg/kg). All patients were maintained on a calcineurin inhibitor, mycophenolic acid, and low-dose prednisone (5 mg/d). To date, none of the older patients experienced acute rejection, whereas one younger patient had an acute rejection episode. Initial hospital stays were equal (older: 7.8 ± 3.2 vs younger: 7.5 ± 4.4 days, P = .35). Within the first 6 months, nine older patients required rehospitalization compared to 15 younger patients (P = .15). Bacterial infections in older and younger recipients were equal including wound (4 vs 0), urine (20 vs 15), lung (1 vs 1), and skin (0 vs 2), respectively. There were two BK viral infections in older patients, whereas there were three viral infections, two cytomegalovirus cases, and one Herpes zoster case in younger patients. Calculated 6-month glomerular filtration rate was equal in both groups (older: 55.7 ± 18.5 vs younger: 52.7 ± 18.5 mL/min). Three-year patient and graft survival rates were equivalent for older and younger patients (86.6% vs 97.6%, respectively). In conclusion, low-dose rATG induction therapy is safe and effective in patients older than 65. When compared to younger patients, low-dose rATG leads to equivalent graft survival and function without incurring excess morbidity in the older population.

Original languageEnglish (US)
Pages (from-to)466-468
Number of pages3
JournalTransplantation Proceedings
Volume43
Issue number2
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Kidney
Antilymphocyte Serum
Rabbits
Therapeutics
Graft Survival
Virus Diseases
thymoglobulin
Transplant Recipients
Survival Rate
Mycophenolic Acid
Morbidity
Herpes Zoster
Immunosuppressive Agents
Prednisone
Cytomegalovirus
Glomerular Filtration Rate
Bacterial Infections
Kidney Transplantation
Population
Length of Stay

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy. / Laftavi, M. R.; Patel, S.; Soliman, M. R.; Alnimri, Muna A; Kohli, R.; Said, M.; Pankewycz, O.

In: Transplantation Proceedings, Vol. 43, No. 2, 03.2011, p. 466-468.

Research output: Contribution to journalArticle

Laftavi, M. R. ; Patel, S. ; Soliman, M. R. ; Alnimri, Muna A ; Kohli, R. ; Said, M. ; Pankewycz, O. / Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy. In: Transplantation Proceedings. 2011 ; Vol. 43, No. 2. pp. 466-468.
@article{3c34023e474e43678d1655eb55602e2a,
title = "Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy",
abstract = "Current immunosuppressive therapies and protocols have led to significant improvements in early patient and graft survival rates following kidney transplantation. Whether induction therapies such as rabbit anti-thymocyte globulin (rATG) contribute to these improved results remains controversial. Full-dose rATG induction therapy (710 mg/kg) has been associated with increased morbidity, which may be especially true in a high-risk population such as the elderly. Therefore, we studied the efficacy and tolerability of a low-dose rATG induction strategy in 45 older recipients (>65 years) compared to 45 concurrently transplanted younger patients (<65 years). Both groups received a similar low-dose of rATG induction therapy (older: 2.96 ± 1.29 vs younger: 3.2 ± 2.11 mg/kg). All patients were maintained on a calcineurin inhibitor, mycophenolic acid, and low-dose prednisone (5 mg/d). To date, none of the older patients experienced acute rejection, whereas one younger patient had an acute rejection episode. Initial hospital stays were equal (older: 7.8 ± 3.2 vs younger: 7.5 ± 4.4 days, P = .35). Within the first 6 months, nine older patients required rehospitalization compared to 15 younger patients (P = .15). Bacterial infections in older and younger recipients were equal including wound (4 vs 0), urine (20 vs 15), lung (1 vs 1), and skin (0 vs 2), respectively. There were two BK viral infections in older patients, whereas there were three viral infections, two cytomegalovirus cases, and one Herpes zoster case in younger patients. Calculated 6-month glomerular filtration rate was equal in both groups (older: 55.7 ± 18.5 vs younger: 52.7 ± 18.5 mL/min). Three-year patient and graft survival rates were equivalent for older and younger patients (86.6{\%} vs 97.6{\%}, respectively). In conclusion, low-dose rATG induction therapy is safe and effective in patients older than 65. When compared to younger patients, low-dose rATG leads to equivalent graft survival and function without incurring excess morbidity in the older population.",
author = "Laftavi, {M. R.} and S. Patel and Soliman, {M. R.} and Alnimri, {Muna A} and R. Kohli and M. Said and O. Pankewycz",
year = "2011",
month = "3",
doi = "10.1016/j.transproceed.2011.01.039",
language = "English (US)",
volume = "43",
pages = "466--468",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy

AU - Laftavi, M. R.

AU - Patel, S.

AU - Soliman, M. R.

AU - Alnimri, Muna A

AU - Kohli, R.

AU - Said, M.

AU - Pankewycz, O.

PY - 2011/3

Y1 - 2011/3

N2 - Current immunosuppressive therapies and protocols have led to significant improvements in early patient and graft survival rates following kidney transplantation. Whether induction therapies such as rabbit anti-thymocyte globulin (rATG) contribute to these improved results remains controversial. Full-dose rATG induction therapy (710 mg/kg) has been associated with increased morbidity, which may be especially true in a high-risk population such as the elderly. Therefore, we studied the efficacy and tolerability of a low-dose rATG induction strategy in 45 older recipients (>65 years) compared to 45 concurrently transplanted younger patients (<65 years). Both groups received a similar low-dose of rATG induction therapy (older: 2.96 ± 1.29 vs younger: 3.2 ± 2.11 mg/kg). All patients were maintained on a calcineurin inhibitor, mycophenolic acid, and low-dose prednisone (5 mg/d). To date, none of the older patients experienced acute rejection, whereas one younger patient had an acute rejection episode. Initial hospital stays were equal (older: 7.8 ± 3.2 vs younger: 7.5 ± 4.4 days, P = .35). Within the first 6 months, nine older patients required rehospitalization compared to 15 younger patients (P = .15). Bacterial infections in older and younger recipients were equal including wound (4 vs 0), urine (20 vs 15), lung (1 vs 1), and skin (0 vs 2), respectively. There were two BK viral infections in older patients, whereas there were three viral infections, two cytomegalovirus cases, and one Herpes zoster case in younger patients. Calculated 6-month glomerular filtration rate was equal in both groups (older: 55.7 ± 18.5 vs younger: 52.7 ± 18.5 mL/min). Three-year patient and graft survival rates were equivalent for older and younger patients (86.6% vs 97.6%, respectively). In conclusion, low-dose rATG induction therapy is safe and effective in patients older than 65. When compared to younger patients, low-dose rATG leads to equivalent graft survival and function without incurring excess morbidity in the older population.

AB - Current immunosuppressive therapies and protocols have led to significant improvements in early patient and graft survival rates following kidney transplantation. Whether induction therapies such as rabbit anti-thymocyte globulin (rATG) contribute to these improved results remains controversial. Full-dose rATG induction therapy (710 mg/kg) has been associated with increased morbidity, which may be especially true in a high-risk population such as the elderly. Therefore, we studied the efficacy and tolerability of a low-dose rATG induction strategy in 45 older recipients (>65 years) compared to 45 concurrently transplanted younger patients (<65 years). Both groups received a similar low-dose of rATG induction therapy (older: 2.96 ± 1.29 vs younger: 3.2 ± 2.11 mg/kg). All patients were maintained on a calcineurin inhibitor, mycophenolic acid, and low-dose prednisone (5 mg/d). To date, none of the older patients experienced acute rejection, whereas one younger patient had an acute rejection episode. Initial hospital stays were equal (older: 7.8 ± 3.2 vs younger: 7.5 ± 4.4 days, P = .35). Within the first 6 months, nine older patients required rehospitalization compared to 15 younger patients (P = .15). Bacterial infections in older and younger recipients were equal including wound (4 vs 0), urine (20 vs 15), lung (1 vs 1), and skin (0 vs 2), respectively. There were two BK viral infections in older patients, whereas there were three viral infections, two cytomegalovirus cases, and one Herpes zoster case in younger patients. Calculated 6-month glomerular filtration rate was equal in both groups (older: 55.7 ± 18.5 vs younger: 52.7 ± 18.5 mL/min). Three-year patient and graft survival rates were equivalent for older and younger patients (86.6% vs 97.6%, respectively). In conclusion, low-dose rATG induction therapy is safe and effective in patients older than 65. When compared to younger patients, low-dose rATG leads to equivalent graft survival and function without incurring excess morbidity in the older population.

UR - http://www.scopus.com/inward/record.url?scp=79953193081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953193081&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2011.01.039

DO - 10.1016/j.transproceed.2011.01.039

M3 - Article

C2 - 21440735

AN - SCOPUS:79953193081

VL - 43

SP - 466

EP - 468

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 2

ER -